Business Wire

First Participants Enrolled in the AriBio USA Phase 3 Registration Trial to Evaluate AR1001 in Early Alzheimer’s Disease

Share

AriBio USA, a clinical-stage biopharmaceutical company, announced the enrollment of their first participants in their Phase 3 trial to evaluate the efficacy of AR1001 in participants with early Alzheimer’s Disease (AD). AR1001 is a blood-brain barrier penetrating small molecule known to inhibit neuron apoptosis and promote neurogenesis, increase neuroplasticity and increase autophagy activity to remove toxic proteins.

This study is a randomized, placebo-controlled, double-blind, multi-center Phase 3 trial that plans to enroll 800 participants from approximately 75 sites for 12 months of treatment, followed by an optional two-year extension phase. Patients will be randomly assigned to receive either 30 mg of AR1001 or placebo once daily for 52 weeks. In the optional-extension study, participants originally assigned to placebo will receive 30 mg of AR1001 for an additional two years of treatment. The primary endpoint in the trial is the Change in the Clinical Dementia Rating Scale – Sum of Boxes (CDR-SB) at Week 52. “As we learn more about Alzheimer’s disease with the understanding that different therapeutic approaches are necessary to demonstrate a meaningful benefit to patients and their caregivers we look forward to data on AR1001,” said Dr. Greeley, CMO for AriBio USA.

“AriBio USA is excited to share this significant milestone, and we look forward to providing regular updates to the program as enrollment progresses in this Phase 3 trial. We continue to engage with interested investigators and sites who are committed to making a difference in the treatment and care of patients with Alzheimer’s disease,” said James Rock, CEO of AriBio USA, Inc. Enrollment is expected to require approximately 2 years for this Phase 3 trial. Dr. Greeley stated, “As we understand more about Alzheimer’s disease, with the understanding that different therapeutics and lifestyle approaches will be necessary to demonstrate a meaningful benefit to patients and their caregivers, we expect AR1001 to be part of this treatment paradigm.”

AriBio Ltd, the parent company of AriBio USA, is committed to developing new therapeutics in the neurology space with a pipeline of PDE-5 inhibitors and other new molecular entities. “Our goal is to transform the treatment options available for patients with dementia to improve their daily lives,” stated Dr. Matthew Choung, CEO of AriBio Ltd.

About AR1001-ADP3-US01

AR1001-ADP3-US01 (NCT05531526) is Phase 3 Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of AR1001 over 52 Weeks in Participants with Early Alzheimer’s Disease. The study aims to assess the efficacy and safety of AR1001 in slowing the progression of Alzheimer's disease through various cognitive and functional assessments. The details of the clinical trial are available at ClinicalTrials.gov.

About AriBio

AriBio Co., Ltd. is a biopharmaceutical company based in South Korea with a focus on the development of therapies for neurodegenerative diseases. AriBio USA, INC. is the subsidiary company of AriBio Co., Ltd. based in San Diego, CA in charge of clinical operations and regulatory affairs for AriBio.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Fred Kim
fredkim@aribiousa.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Large Real-World, Multi-Center Study Demonstrates Viz.ai Platform Saves Critical Minutes in Stroke Care8.2.2023 17:15:00 EET | Press release

Viz.ai, the leader in AI-powered disease detection and care coordination, and TeleSpecialists LLC, a physician-owned management service organization committed to providing exceptional emergent and non-emergent neurology and psychiatric patient care via telemedicine, announced new data presented today at the International Stroke Conference (ISC) from the VALIDATE (Validation of Artificial intelligence to LImit Delays in Acute stroke Treatment and Endovascular therapy) study. The study demonstrated that hospital utilization of Viz’ AI-powered care coordination platform was associated with a 39.5 minute reduction in patient arrival to time of first contact with the neurointerventionalist for need for potential emergency endovascular treatment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230208005564/en/ VALIDATE Study: Median Arrival to Neurointerventionalist Notification Times (Graphic: Business Wire) “In the world of strok

OAG Launches Flight Status Alerts, An All-New View of Immediate Flight Changes8.2.2023 17:15:00 EET | Press release

OAG, the world’s leading provider of travel data and insight, today announced the launch of its new Flight Status Alerts, which delivers an all-new view of immediate flight changes. Flight Status Alerts directly integrates into OAG’s Flight Info Platform, which already provides a continuous stream of flight schedule changes. Flight Status Data together with Flight Schedules now delivers the broadest possible coverage of flight information to OAG customers which include booking engines, travel and hospitality apps, airline apps, online travel agencies, metasearch, search engines and flight tracking apps. This powerful combination provides a first-of-its-kind flight window into key schedules and status data – from the moment a flight is scheduled to when luggage hits the baggage belt, and everything in between. Powered by Microsoft’s Azure Event Hub, the advanced technology delivers speed and scale to notifications on OAG’s Flight Info Platform. It processes an average of 40 updates each

Wemade Hosts WEMIX Airdrop Event to Celebrate the Global Launch of MIR M!8.2.2023 17:00:00 EET | Press release

WEMIX PLAY, the number 1 blockchain gaming platform by Wemade, is hosting a WEMIX airdrop event until February 28th to celebrate the global launch of its MMORPG, MIR M: Vanguard and Vagabond. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230208005349/en/ WEMIX PLAY, the number 1 blockchain gaming platform by Wemade, is hosting a WEMIX airdrop event until February 28th to celebrate the global launch of its MMORPG, MIR M: Vanguard and Vagabond. (Graphic: Business Wire) WEMIX PLAY will be giving away 1 WEMIX each to 1 million users who meet the following requirements: Connect game account to PLAY Wallet, reach character level 25, and have a log-in record within one week from the event end date. If the number of participants exceeds 1 million, winners will be selected based on the order of reaching character level 25 first. Winners and more information will be announced later. MIR M is a K-MMORPG featuring martial arts that lau

Ionblox increases Series B to $32m with investment from Lilium, Applied Ventures, Temasek and Catalus Capital8.2.2023 17:00:00 EET | Press release

Ionblox, a next-generation lithium-ion battery company announced a second close of its Series B round at an increased $32 million. Strategic partners include original investors Lilium and Applied Ventures who were joined by Temasek and Catalus Capital. The company will use the increased Series B funding to scale its technology, develop advanced high-power cells for electric aviation, and prototype fast-charge cells for Electric Vehicles. The company’s batteries are developed with high-performance lithium-ion cells that have pre-lithiated silicon dominant anodes. The batteries can address the most demanding use cases such as electric Vertical Take-off and Landing Aircrafts or eVTOL. Ionblox’s pre-lithiated Silicon anode technology enables a groundbreaking combination of up to 50% higher energy density, 5X more power, and an extreme fast charge of 10 minutes compared with conventional lithium-ion cells. Ionblox is currently producing its large format pouch cells of up to 50Ah on its pilo

LivaNova Initiates Limited Commercial Release in Europe of the Essenz Perfusion System for Cardiopulmonary Bypass Procedures8.2.2023 17:00:00 EET | Press release

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced the start of a limited commercial release for the Essenz™ Perfusion System*. The release has been initiated in select centers throughout Europe, following a successful clinical experience in two major centers, Catharina Hospital in Eindhoven, Netherlands and San Donato Hospital in Milan, Italy. Consisting of a next-generation heart-lung machine (HLM) and a transformative patient monitor, Essenz puts data at the forefront to deliver a patient-tailored approach that supports data-driven decisions during life-saving cardiopulmonary bypass (CPB) procedures. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230208005127/en/ LivaNova's Essenz™ Perfusion System (Photo: Business Wire) Catharina Hospital was the first hospital in the world to carry out clinical cases with the Essenz Perfusion System. “We are proud to be the first to

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom